Clinical Trial Update: Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma [Phase 2]

View source ↗

Summary

Phase II study of the monoclonal antibody ch14.18/CHO given by continuous infusion in patients with primary refractory or relapsed neuroblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• ch14.18/CHO

Snippet

Sponsor: University Medicine Greifswald | Conditions: Neuroblastoma | Phase 2 | Status: UNKNOWN